Use of post-exposure prophylaxis after occupational exposure to Zaire ebolavirus

Authors

• Karen K. Wong, U.S. Centers for Disease Control and Prevention, AtlantaFollow
• Richard T. Davey, National Institutes of Health, Bethesda, Maryland
• Angela L. Hewlett, University of Nebraska Medical Center
• Colleen S. Kraft, Emory University, Atlanta
• Aneesh K. Mehta, Emory University, Atlanta
• Mark J. Mulligan, Emory University, Atlanta
• Allison Beck, Emory University, Atlanta
• William Dorman, US Army Medical Research Institute of Infectious Diseases, Frederick, Maryland
• Christopher J. Kratochvil, University of Nebraska Medical Center, Omaha
• Lilin Lai, Emory University, Atlanta
• Tara N. Palmore, National Institutes of Health, Bethesda, Maryland
• Susan Rogers, Emory University, Atlanta, Georgia
• Philip W. Smith, University of Nebraska Medical Center, OmahaFollow
• Anthony F. Suffredini, Critical Care Medicine Department, Clinical Center, National Institutes of Health
• Mark Wolcott, US Army Medical Research Institute of Infectious Diseases, Frederick
• Ute Ströher, U.S. Centers for Disease Control and Prevention, Atlanta
• Timothy M. Uyeki, U.S. Centers for Disease Control and Prevention, AtlantaFollow

Date of this Version

2016

Citation

Clinical Infectious Diseases (2016) doi: 10.1093/cid/ciw256.

Comments

US government work

Abstract

From September 2014–April 2015, six persons who had occupational exposures to Zaire ebolavirus in West Africa received investigational agents rVSV-ZEBOV or TKM-100802 for post-exposure prophylaxis and were monitored in the U.S. All patients experienced self-limited symptoms after PEP; none developed Ebola virus disease.